Arkolith/Insider Trading/CRNX/Form 4

Struthers Richard Scott

President & CEO, DirectorCrinetics Pharmaceuticals, Inc. (CRNX) · full profile →Form 4 · filed Dec 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 18, 2025Option exercise(M)28K$15.29$434K365K
Dec 18, 2025Option exercise(M)16K$9.28$152K336K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 18, 2025Option exercise(M)16K—$00
Dec 18, 2025Option exercise(M)28K—$0259K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-058056) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML